Cassava Sciences, Inc. Board of Directors

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Mr. Richard Jon Barry

Mr. Richard Jon Barry

CEO, President & Director

Ms. Freda Nassif

Ms. Freda Nassif

Chief Business Officer & Chief Commercial Officer

Mr. Eric J. Schoen

Mr. Eric J. Schoen

Chief Financial Officer

Dr. Michael Marsman Pharm.D.

Dr. Michael Marsman Pharm.D.

Senior Vice President of Regulatory Affairs

Mr. R. Christopher Cook J.D.

Mr. R. Christopher Cook J.D.

Senior VP, Company Secretary & General Counsel

Dr. George Thornton Ph.D.

Dr. George Thornton Ph.D.

Senior Vice President of Technology

Jaren Landen

Jaren Landen

Chief Clinical Development Officer

Mr. Michael Zamloot

Mr. Michael Zamloot

Senior Vice President of Technical Operations

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.